Mobile

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Mise à jour : Il y a 4 ans
Référence : NCT02045602

Femme et Homme

  • | Pays :
  • Spain
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The purpose of this study is to determine the safety and tolerability of VCN-01 either administered alone or in combination with Abraxane®/Gemcitabine, and to determine the recommended phase II dose of VCN-01 alone or in combination with Abraxane®/Gemcitabine.

Critère d'inclusion

  • Locally Advanced Solid Tumors ,Metastatic Solid Tumors ,PANCREATIC ADENOCARCINOMA'

Liens